Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 4/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483094 | 0.82 | SLC7A5 (0.66) | SLC7A5SIRT5HSD17B10USP2ADORA3 | |
| SCHEMBL1483095 | 0.82 | SLC7A5 (0.66) | SLC7A5SIRT5HSD17B10USP2ADORA3 | |
| SCHEMBL5566682 | 0.79 | SLC7A5 (0.57) | SLC7A5HSD17B10USP2ADORA3ALOX15 | |
| SCHEMBL6024170 | 0.78 | SLC7A5 (0.61) | SLC7A5HSD17B10USP2ADORA3ALOX15 | |
| SCHEMBL12803446 | 0.78 | SLC7A5 (0.56) | SLC7A5SIRT5HSD17B10USP2ADORA3 | |
| SCHEMBL10064656 | 0.78 | SLC7A5 (0.56) | SLC7A5SIRT5HSD17B10USP2ADORA3 | |
| SCHEMBL5560750 | 0.78 | SLC7A5 (0.56) | SLC7A5SIRT5HSD17B10USP2ADORA3 | |
| SCHEMBL31524255 | 0.78 | SLC7A5 (0.56) | SLC7A5SIRT5HSD17B10USP2ADORA3 | |
| SCHEMBL5560150 | 0.75 | SLC7A5 (0.53) | SLC7A5SIRT5HSD17B10USP2ADORA3 | |
| SCHEMBL16861128 | 0.74 | SLC7A5 (0.50) | SLC7A5SIRT5HSD17B10USP2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189383-B2 | Radioactively labelled amino acid analogues, their preparation and use | MALLINCKRODT INC. | 2007-03-13 | — | — | US | claimed |
| US-20060127306-A1 | Radioactively labelled amino acid analogues, their preparation and use | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2006-06-15 | — | — | US | claimed |
| US-20070081941-A1 | F-18 Labeled Amino Acid Analogs | MALLINCKRODT INC. (US) | 2007-04-12 | — | — | US | disclosed |
| US-7189383-B2 | Radioactively labelled amino acid analogues, their preparation and use | MALLINCKRODT INC. | 2007-03-13 | — | — | US | disclosed |
| US-20060127306-A1 | Radioactively labelled amino acid analogues, their preparation and use | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070081941-A1 | F-18 Labeled Amino Acid Analogs | BCAT1, BCAT2, SLC1A5 | SLC7A5 9/4885SIRT5 4156/4885HSD17B10 2197/4885 |
| US-20060127306-A1 | Radioactively labelled amino acid analogues, their preparation and use | BCAT1, BCAT2, SLC1A5 | SLC7A5 8/4885SIRT5 3652/4885HSD17B10 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.